Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 05 2021 - 10:41AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
Commission
File Number 000-54586
NOTIFICATION
OF LATE FILING
(Check one):
|
☒ Form 10-K
☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form
N-SAR ☐ Form N-CAR
|
For
Period Ended: December 31, 2020
|
☐
|
Transition
Report on Form 10-K
|
|
☐
|
Transition
Report on Form 20-F
|
|
☐
|
Transition
Report on Form 11-K
|
|
☐
|
Transition
Report on Form 10-Q
|
|
☐
|
Transition
Report on Form N-SAR
|
For
the Transition Period Ended: ________________________________________________________
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
Boston
Therapeutics, Inc.
Full
name of registrant
Former
name if applicable
354
Merrimack Street, #4
Address
of principal executive office
Lawrence,
Massachusetts 01843
City,
state and zip code
PART
II - RULE 12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25
(b), the following should be completed. (Check box if appropriate.)
|
(a)
|
The reasons described in reasonable
detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☒
|
(b)
|
The subject
annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K, Form N-SAR, Form N-CSR, or portion thereof, will be filed
on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report
on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following
the prescribed due date; and
|
|
(c)
|
The accountant’s
statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed
within the prescribed time period.
The
Company’s Annual Report on Form 10-K for the period ended December 31, 2019 cannot be filed within the prescribed time period because
the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included
in the Form 10-K. The Company’s Annual Report on Form 10-K will be filed on or before the 15th calendar day following
the prescribed due date.
Part
IV
Other
Information
(1)
Name and telephone number of person to contact in regard to this notification
Conroy Cheng, Interim CEO
|
|
(603)
|
|
935-9799
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
☒ Yes ☐
No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
☐ Yes ☒
No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Boston
Therapeutics, Inc.
Name
of Registrant as Specified in Charter.
Has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 1, 2021
|
By:
/s/ Conroy Cheng
|
|
Conroy Cheng
|
|
Interim Chief Executive Officer
|
3